TY - JOUR AU - Russo, Alessandro AU - Scilla, Katherine A. AU - Rolfo, Christian PY - 2019 TI - Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial JF - Translational Cancer Research; Vol 8, Supplement 6 (December 20, 2019): Translational Cancer Research Y2 - 2019 KW - N2 - Treatment of advanced non-small cell lung cancer (NSCLC) has evolved considerably over the past two decades, with improved survival outcomes in a significant proportion of patients due to the development of new effective systemic therapies. The refinement of the therapeutic approach with a molecularly-based strategy has led to unprecedented results in selected patient populations harboring actionable oncogene drivers (~20–25% of all NSCLC patients). UR - https://tcr.amegroups.org/article/view/29780